Nussbaum, S.R., Zahradnik, R.J., Lavigne, J.R., Brennan, G.L., Nozawa-Ung, K., Kim, L.Y., et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin. Chem. 33 (1987), 1364–1367.
Cavalier, E., Delanaye, P., Vranken, L., Bekaert, A.-C., Carlisi, A., Chapelle, J.-P., et al. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. Nephrol. Dial. Transplant. 27 (2011), 1950–1956, 10.1093/ndt/gfr535.
Rasmussen, H., Effect of oxidation and reduction upon the biological activity of parathyroid hormone. Science 128 (1958), 1347–1348, 10.1126/science.128.3335.1347.
Westhuyzen, J., Adams, C.E., Fleming, S.J., Evidence for oxidative stress during in vitro dialysis. Nephron 70 (1995), 49–54, 10.1159/000188543.
Ursem, S.R., Vervloet, M.G., Hillebrand, J.J.G., De Jongh, R.T., Heijboer, A.C., Oxidation of PTH: in vivo feature or effect of preanalytical conditions?. Clin. Chem. Lab. Med. 56 (2018), 249–255, 10.1515/cclm-2017-0313.
Cavalier, E., Delanaye, P., Moranne, O., Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making. Am. J. Kidney Dis. 61 (2013), 847–848, 10.1053/j.ajkd.2012.12.013.
Hocher, B., Godes, M., Reichetzeder, C., Tsuprykov, O., Chertow, G., Parfrey, P., et al. Non-oxidized PTH (n-oxPTH) is associated with cardiovascular events and all-cause mortality in patients with secondary hyperparathyroidism undergoing hemodialysis who participated in the EVOLVE trial. J. Am. Soc. Nephrol., 25, 2014.
Hocher, B., Armbruster, F.P., Stoeva, S., Reichetzeder, C., Grön, H.J., Lieker, I., et al. Measuring parathyroid hormone (PTH) in patients with oxidative stress – do we need a fourth generation parathyroid hormone assay?. PLoS One, 7, 2012, e40242-, 10.1371/journal.pone.0040242.
